TABLE 5.

Summary of GSK3358699 dose proportionality model in part A ^a of the study (pharmacokinetic population ^b )

PK parameter	Slope (SE)	90% CI for slope	Fold increase for doubling dose	90% CI for fold increase
AUC(0‐t), h*ng/mL	1.2 (0.05)	(1.2, 1.3)	2.4	(2.2, 2.5)
AUC(0‐∞), h*ng/mL	1.5 (0.1)	(1.2, 1.7)	2.7	(2.3, 3.3)
C max, ng/mL	1.1 (0.1)	(0.9, 1.2)	2.1	(1.9, 2.3)

AUC_(0‐t), area under the concentration‐time curve from time zero to the time of the last quantifiable concentration; AUC_(0‐∞), area under the concentration‐time curve extrapolated to infinity; CI, confidence interval; C _max, maximum observed concentration; PK, pharmacokinetic; SE, standard error.

^a Part A was a single ascending‐dose crossover study in two interlocking cohorts. Each participant received a maximum of two single ascending oral doses of GSK3358699 (1, 3, 10, 20, 40 or 30 mg) and one dose of placebo.

^b The pharmacokinetic population included all participants who received an active dose of the study drug and for whom pharmacokinetic samples were obtained and analysed.